Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Merck, GSK Sarcoma Drugs Bring Different Efficacy Stories To FDA Panel Review

Mar 16 2012

• By Sue Sutter

Related Content

FDA Panel Review Of Merck/Ariad’s Sarcoma Drug Could Hinge On Clinical Significance Of Progression-Free Survival Benefit

Feb 03 2012

Ariad Comes Of Age With Oncology Drugs, Readies For Commercial Leap

Jun 27 2011

Ariad Opts-in To Co-Promote mTOR With Merck

Mar 18 2011

Related Companies

Merck & Co., Inc.

ARIAD Pharmaceuticals, Inc.

GSK plc

Genentech, Inc.

Additional Topics

Advisory Committees BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window